Testosterone clinic marketing: FDA labeling, Schedule III and ad rules

Men’s health clinics that offer testosterone therapy compete in a crowded, heavily advertised market. Much of the advertising in this space promises energy, muscle, drive and youth. Those promises are exactly where a clinic gets into trouble, because testosterone is a prescription drug with specific approved uses, a controlled substance under federal law, and a restricted category on every major ad platform.

This guide covers what the FDA says testosterone is approved for, what Schedule III status means for marketing and telehealth, how Google and Meta treat ads for prescription drugs, and how to write claims you can stand behind. It does not cover who should receive testosterone or how it is prescribed; those are clinical decisions for your providers. Clinics that sell healthy aging programs should read longevity clinic marketing.

What testosterone is approved for

The FDA states that testosterone is approved solely for use in men who lack or have low testosterone levels in conjunction with an associated medical condition. Approved forms include oral, topical gel, transdermal patch, buccal and injection products.

On February 28, 2025, the FDA announced class-wide labeling changes for testosterone products after the TRAVERSE trial and required blood pressure studies. According to the FDA, the changes add the TRAVERSE results to all testosterone labeling, remove language from the Boxed Warning about an increased risk of adverse cardiovascular outcomes, add warnings or product-specific information about increased blood pressure, and keep the Limitation of Use language for age-related hypogonadism.

For marketing, that last point matters most. The FDA kept the limitation on age-related low testosterone in place, so advertising that presents testosterone as a general treatment for aging, tiredness or lower drive in otherwise healthy men goes beyond what the labeling supports. Removing one cardiovascular warning is not a basis for saying testosterone is safe, and the new blood pressure warnings point the other way.

Schedule III and what it changes

Testosterone is a controlled substance. Under 21 CFR 1300.01, an anabolic steroid is any drug or hormonal substance chemically and pharmacologically related to testosterone, other than estrogens, progestins, corticosteroids and DHEA, and 21 CFR 1308.13(f) places anabolic steroids in Schedule III.

That status shapes marketing in three ways. Prescribing requires a DEA-registered practitioner. Ad platforms treat it as a prescription drug, and often apply extra scrutiny to controlled substances. And telehealth prescribing falls under the DEA’s telemedicine rules, covered next.

Telehealth prescribing and the DEA date

HHS’s page on prescribing controlled substances via telehealth says the DEA, jointly with HHS, has extended the full set of COVID-19 era telemedicine flexibilities for prescribing controlled medications through December 31, 2026. Under those flexibilities, a DEA-registered practitioner can prescribe a Schedule II to V controlled substance by telemedicine without a prior in-person medical evaluation if required conditions are met. The page links the Federal Register notice of the fourth temporary extension, published December 31, 2025.

A testosterone program built on telehealth-only starts depends on that date. Do not market an online-only testosterone service without counsel confirming what will apply after December 31, 2026, and plan for your pages, ads and intake to change if the rules do. Our guide to telehealth marketing for practices covers state licensure and the other telehealth rules.

Google and Meta ad rules

Google’s Healthcare and medicines policy restricts ads for prescription drug services, including online pharmacies and telemedicine providers, and requires advertisers to apply for certification before those ads can run. It also restricts prescription drug terms in ads, landing pages and keywords, and its list of unapproved substances includes products containing hCG when promoted in conjunction with anabolic steroids.

Meta’s Drugs and Pharmaceuticals ad standard requires advertisers promoting prescription drugs, including telehealth providers, to provide evidence that they are appropriately licensed. It says qualified advertisers actively certified with LegitScript can run such ads if they target only people 18 or older and only in countries where they are certified.

In practice, a clinic should expect to go through certification before running ads that mention testosterone, and should write ads about the clinic and its evaluation process rather than about the drug. Our Google Ads for practices page explains how we handle restricted healthcare categories, and the healthcare ad policy basics guide covers the platform rules in more detail.

Claims you can stand behind

The FTC Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, generally randomized, controlled human clinical testing, and that the claims you imply count as much as the ones you state. In a men’s health clinic, implied claims often come from images and taglines rather than words.

• Avoid promises of results: more energy, more muscle, better performance, feeling decades younger.
• Avoid before and after photos and transformation stories. Under 16 CFR 255.2, an endorsement about results will likely be read as saying what other patients will generally achieve, so you need evidence for that before you use it.
• Do not describe testosterone as safe, natural or side-effect free.
• Do not present symptoms lists as a self-diagnosis tool that leads straight to treatment.
• Do not compare compounded products to FDA-approved ones as equivalent, and do not use drug brand names in ads. For testosterone pellets, see hormone pellet therapy marketing.

What you can say is what the clinic does: the evaluation, the lab testing your providers order, who reviews the results, how follow-up works and what the visit costs. Describe the decision as the provider’s, after evaluation. For how this plays out in a related field, see our guide to weight loss clinic marketing.

What tends to work, inside the rules

1. An honest evaluation page. What a first visit includes, what testing is done, and that treatment depends on the provider’s evaluation.
2. Clear pricing. Visit and lab costs, and what is and is not included, so patients are not surprised.
3. Provider credentials. Who your clinicians are, their licenses and how follow-up works.
4. Location and hours. A complete Google Business Profile and a page for each location, as covered on our healthcare SEO page.
5. Search ads after certification. Ads about the clinic and its evaluation process, sent to a page that matches the ad.
6. Privacy by default. Keep advertising pixels off intake and booking pages; see our guide to tracking pixels on practice websites.

Sources

• FDA: FDA issues class-wide labeling changes for testosterone products (February 28, 2025)
• 21 CFR 1308.13: Schedule III (paragraph f, anabolic steroids)
• 21 CFR 1300.01: Definitions (anabolic steroid)
• HHS: Prescribing controlled substances via telehealth (last updated January 5, 2026)
• Federal Register (December 31, 2025): Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
• Google Ads: Healthcare and medicines policy
• Meta: Drugs and Pharmaceuticals ad standard
• FTC: Health Products Compliance Guidance
• 16 CFR 255.2: Consumer endorsements

More in Cash-pay, aesthetic and wellness care